Different treatment efficacies and T790M acquisition of EGFR‐TKIs on NSCLC patients with variable Del‐19 subtypes of EGFR
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Cancer"
DOI: 10.1002/ijc.34507
Abstract: EGFR exon 19 deletion (Del‐19) comprises multiple advanced NSCLC subtypes. EGFR‐tyrosine kinase inhibitor (TKI) efficacy and T790M acquisition in various Del‐19 subtypes is unknown. We prospectively collected tissue samples from patients harboring NSCLC with Del‐19… read more here.
Keywords: t790m acquisition; del; egfr tkis; del subtypes ... See more keywords